Document is current
Any future updates will be listed below
-
Authors
Bonora, Benedetta Maria
Vigili de Kreutzenberg, Saula
Avogaro, Angelo
Fadini, Gian Paolo https://orcid.org/0000-0002-6510-2097
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02327039 at ClinicalTrials.govDocuments that mention this clinical trial
Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
https://doi.org/10.1186/s12933-019-0910-5
Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
https://doi.org/10.1186/s12933-017-0529-3
-
Funding
Funding for this research was provided by:
AstraZeneca (ESR-14-10088)
- License Information
-
More Information
Article History
Received: 13 June 2019
Accepted: 8 August 2019
First Online: 14 August 2019
Ethics approval and consent to participate
: The study was approved by the Ethical Committee of the University Hospital of Padova (No. 3302/AO/14). All participants signed a written informed consent.
: Not applicable.
: B.M.B. received lecture or advisory board fees from Astra Zeneca, Eli Lilly, Boehringer Ingelheim, Novo Nordisk and Novartis, G.P.F. received grant support, lecture fees, or advisory board fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, Genzyme, Abbott, Novartis, and Merck Sharp & Dohme. A.A. received research grants, lecture fees, or advisory board fees from Merck Sharp & Dome, AstraZeneca, Novartis, Boeringher Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Eli Lilly, Servier, and Takeda. The remaining authors have nothing to disclose.
